{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=87", "query": { "condition": "Melanoma Neoplasms", "page": 87 }, "page_size": 10 }, "pagination": { "page": 87, "page_size": 10, "total_count": 2209, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=88&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=86&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T01:47:00.487Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05361174", "title": "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Melanoma", "Metastatic Melanoma", "Stage III Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "IOV-4001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 53, "start_date": "2022-07-20", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 11, "location_summary": "Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05361174" }, { "nct_id": "NCT02027961", "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2013-12-20", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-05-17", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027961" }, { "nct_id": "NCT01068470", "title": "Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma", "Kidney Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2009-11", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2014-05-29", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 1, "location_summary": "Beaumont, California", "locations": [ { "city": "Beaumont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068470" }, { "nct_id": "NCT03864042", "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Melanoma" ], "interventions": [ { "name": "losartan", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "rosuvastatin", "type": "DRUG" }, { "name": "bupropion immediate release (IR)", "type": "DRUG" }, { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "modafinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-01-02", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hopkins", "state": "Minnesota" }, { "city": "Maple Grove", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03864042" }, { "nct_id": "NCT06697301", "title": "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "EIK1001", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA® )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 740, "start_date": "2025-05-22", "completion_date": "2040-12", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 14, "location_summary": "Chandler, Arizona • Hot Springs, Arkansas • Los Angeles, California + 11 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06697301" }, { "nct_id": "NCT00327600", "title": "Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "imexon", "type": "DRUG" }, { "name": "DTIC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AmpliMed Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2005-07", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2010-09-15", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00327600" }, { "nct_id": "NCT01092728", "title": "Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Surgical Resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2011-03", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-09-05", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01092728" }, { "nct_id": "NCT07675967", "title": "Clonal Hematopoiesis Chemotherapy and Radiation Effects Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer (Diagnosis)", "Osteochondroma", "Spitz Nevus", "Solid Cancers", "Breast Cancer", "Gastric (Stomach) Cancer", "Colorectal (Colon or Rectal) Cancer", "Sarcoma", "Ovarian Adenocarcinoma", "Uterine Adenocarcinoma", "Endometrial Adenocarcinoma", "Esophageal Adenocarcinoma", "Head and Neck Cancer", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related MDS", "Clonal Hematopoiesis of Indeterminate Potential (CHIP)", "Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Samples", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2025-04-04", "completion_date": "2035-03-31", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675967" }, { "nct_id": "NCT04700072", "title": "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab/Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 56, "start_date": "2021-05-03", "completion_date": "2025-10-17", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 9, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04700072" }, { "nct_id": "NCT02224781", "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Recurrent Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2015-09-08", "completion_date": "2026-12-19", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-05T01:47:00.487Z", "location_count": 838, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02224781" } ] }